Wolverine Asset Management’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-14,700
Closed -$263K 1791
2025
Q1
$263K Sell
14,700
-4,000
-21% -$81.2K ﹤0.01% 972
2024
Q4
$326K Buy
18,700
+12,400
+197% +$219K ﹤0.01% 940
2024
Q3
$88.1K Buy
6,300
+3,700
+142% +$38.5K ﹤0.01% 1123
2024
Q2
$21.4K Buy
2,600
+1,300
+100% +$8.76K ﹤0.01% 1259
2024
Q1
$10K Sell
1,300
-15,100
-92% -$127K ﹤0.01% 1298
2023
Q4
$147K Sell
16,400
-900
-5% -$6.55K ﹤0.01% 1084
2023
Q3
$155K Buy
17,300
+2,500
+17% +$35.3K ﹤0.01% 1085
2023
Q2
$227K Buy
14,800
+4,700
+47% +$85.5K ﹤0.01% 979
2023
Q1
$227K Sell
10,100
-16,600
-62% -$353K ﹤0.01% 1013
2022
Q4
$562K Hold
26,700
0.01% 919
2022
Q3
$657K Sell
26,700
-13,600
-34% -$351K 0.01% 934
2022
Q2
$976K Buy
40,300
+6,600
+20% +$166K 0.01% 793
2022
Q1
$868K Buy
+33,700
New +$895K 0.01% 802
2019
Q4
Sell
-1,600
Closed -$18K 1518
2019
Q3
$18K Hold
1,600
﹤0.01% 1281
2019
Q2
$32K Buy
+1,600
New +$31.6K ﹤0.01% 1236

Other funds holding TVTX

Wolverine Asset Management's TVTX Position: Q3 2019 in Review

Wolverine Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2019, closing a stake of 14,661 shares — an estimated $242K sold.

Wolverine Asset Management first reported a position in TVTX in Q2 2019 and held it in 1 quarter. The position peaked at $294K in Q2 2019. 130 funds tracked by Wall St. Rank hold TVTX as of Q3 2019.

  • Wolverine Asset Management reported no remaining Travere Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wolverine Asset Management sold 14,661 Travere Therapeutics shares in Q3 2019, an estimated $242K.
  • Wolverine Asset Management first reported a position in Travere Therapeutics in Q2 2019 and held it in 1 quarter.
  • Wolverine Asset Management's Travere Therapeutics position peaked at $294K in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2019.

Based on Wolverine Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.